Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
J. Clin. Oncol 2022 Nov 04;[EPub Ahead of Print], J Pfisterer, F Joly, G Kristensen, J Rau, S Mahner, P Pautier, A El-Balat, JE Kurtz, U Canzler, J Sehouli, ML Heubner, AD Hartkopf, K Baumann, A Hasenburg, LC Hanker, A Belau, B Schmalfeldt, D Denschlag, TW Park-Simon, F Selle, C Jackisch, A Burges, HJ Lück, G Emons, W Meier, M Gropp-Meier, W Schröder, N de Gregorio, F Hilpert, P HarterFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.